Expiration Date: May 31, 2017
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to inform physicians about the recent advances, as well as anticipated advances in the field of lung cancer treatment.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, pulmonary care specialists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with lung cancer. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other health care providers interested in the treatment of lung cancer are also invited to participate.
Learning ObjectivesAfter participating in this CME/CE activity, learners should be better prepared to:
- Discuss biologically targeted treatment personalization in lung cancer
- Review the emerging role of liquid biopsy in the near future with respect to lung cancer treatment
- Assess the potential impact of ongoing clinical trials/emerging data on the targeted treatment of lung cancer
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Benjamin Levy, MD
Assistant Professor, Icahn School of Medicine
Medical Director, Thoracic Oncology Program, Mount Sinai Health Systems
Associate Director, Cancer Clinical Trials Office, Mount Sinai Hospital
Mount Sinai Hospital
New York, NY
Disclosure:Consultant: Celgene, AstraZeneca, Lilly, Genentech, Pfizer, Merck; Speaker’s Bureau: Lilly, Genentech.
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This continuing medical and nursing education activity may or may not discuss investigational, unapproved or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise